Healthcare · Biotechnology
Price
$8.75
Market Cap
$2.0B
Employees
685
Beta
0.73
Avg Volume
6,224,246
CEO
Adam S. Grossman
Business Description
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
Business History
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
14.11
Stock Price: $8.75
EPS (Diluted): 0.62
EPS (Diluted): 0.62
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
9.11
Stock Price: $8.75
Total Equity: $477.32M
Shares: 244,904,640
Total Equity: $477.32M
Shares: 244,904,640
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
21.93
Market Cap: $2.03B
Total Debt: $72.14M
Cash: $87.63M
EBITDA: $197.86M
Total Debt: $72.14M
Cash: $87.63M
EBITDA: $197.86M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$4.3B
Market Cap: $2.03B
Total Debt: $72.14M
Cash: $87.63M
Total Debt: $72.14M
Cash: $87.63M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
57.4%
Gross Profit: $292.77M
Revenue: $510.17M
Revenue: $510.17M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
37.5%
Operating Income: $191.44M
Revenue: $510.17M
Revenue: $510.17M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
28.8%
Net Income: $146.93M
Revenue: $510.17M
Revenue: $510.17M
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
30.8%
Net Income: $146.93M
Total Equity: $477.32M
Total Equity: $477.32M
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
33.3%
Operating Income: $191.44M
Tax Rate: 19.6%
Equity: $477.32M
Total Debt: $72.14M
Cash: $87.63M
Tax Rate: 19.6%
Equity: $477.32M
Total Debt: $72.14M
Cash: $87.63M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
6.71
Current Assets: $466.51M
Current Liabilities: $69.54M
Current Liabilities: $69.54M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.15
Short-Term Debt: $2.81M
Long-Term Debt: $69.33M
Total Debt: $72.14M
Total Equity: $477.32M
Long-Term Debt: $69.33M
Total Debt: $72.14M
Total Equity: $477.32M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$2.08
Revenue: $510.17M
Shares: 244,904,640
Shares: 244,904,640
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$1.95
Total Equity: $477.32M
Shares: 244,904,640
Shares: 244,904,640
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$0.11
Operating CF: $50.40M
CapEx: -$22.58M
Shares: 244,904,640
CapEx: -$22.58M
Shares: 244,904,640
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $8.75
Stock Price: $8.75
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $146.93M
Net Income: $146.93M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares ADMA against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 7:50pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $80.9M | $154.1M | $258.2M | $426.5M | $510.2M |
| Cost of Revenue | $79.8M | $118.8M | $169.3M | $206.9M | $217.4M |
| Gross Profit | $1.2M | $35.3M | $88.9M | $219.6M | $292.8M |
| Operating Expenses | $59.5M | $74.6M | $67.3M | $80.6M | $101.3M |
| Operating Income | -$58.4M | -$39.4M | $21.6M | $139.0M | $191.4M |
| Net Income | -$71.6M | -$65.9M | -$28.2M | $197.7M | $146.9M |
| EBITDA | -$53.1M | -$39.5M | $5.1M | $147.7M | $197.9M |
| EPS | $-0.61 | $-0.43 | $-0.13 | $0.85 | $0.62 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:50pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $51.1M | $86.5M | $51.4M | $103.1M | $87.6M |
| Total Current Assets | $208.7M | $270.4M | $257.0M | $331.4M | $466.5M |
| Total Assets | $276.3M | $348.5M | $329.2M | $488.7M | $624.2M |
| Current Liabilities | $30.4M | $39.3M | $49.8M | $55.5M | $69.5M |
| Long-Term Debt | $94.9M | $142.8M | $130.6M | $72.3M | $69.3M |
| Total Liabilities | $135.1M | $196.5M | $194.0M | $139.7M | $146.9M |
| Total Equity | $141.2M | $152.0M | $135.2M | $349.0M | $477.3M |
| Retained Earnings | -$412.1M | -$478.0M | -$506.3M | -$308.6M | -$161.7M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:50pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$112.4M | -$59.5M | $8.8M | $118.7M | $50.4M |
| Capital Expenditure | -$13.5M | -$13.9M | -$5.0M | -$8.6M | -$22.6M |
| Free Cash Flow | -$125.9M | -$73.4M | $3.8M | $110.1M | $27.8M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $1.0M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | -$1.4M | $0 | -$31.9M |
| Net Change in Cash | -$4.8M | $35.4M | -$35.2M | $51.8M | -$15.5M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 6:46pm (14h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$667.0M $629.9M – $704.1M
|
$729.0M $701.9M – $756.1M
|
$838.0M $786.9M – $901.3M
|
$953.7M $895.6M – $1.0B
|
| EBITDA |
-$21.1M -$22.3M – -$20.0M
|
-$23.1M -$24.0M – -$22.2M
|
-$26.5M -$28.6M – -$24.9M
|
-$30.2M -$32.5M – -$28.4M
|
| Net Income |
$252.6M $216.8M – $277.6M
|
$312.7M $277.0M – $408.8M
|
$364.1M $335.3M – $399.9M
|
$443.3M $408.2M – $486.9M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:50pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +90.4% | +67.6% | +65.2% | +19.6% |
| Gross Profit Growth | +2,906.4% | +152.2% | +146.8% | +33.3% |
| Operating Income Growth | +32.6% | +155.0% | +542.5% | +37.7% |
| Net Income Growth | +8.0% | +57.2% | +800.0% | -25.7% |
| EBITDA Growth | +25.6% | +113.0% | +2,784.6% | +34.0% |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for ADMA — it's generated by the pipeline (
market-narrative step).
No community reviews yet for ADMA.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30